Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alzamend NeuroALZN +0.75%21 5-Year Yield-on-Cost % is 0.00 as of Jul. 28, 2026. GuruFocus rates ALZN with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 150 Biotechnology companies, Alzamend Neuro ranks worse than 666666% on this metric.
Alzamend Neuro's yield on cost for the quarter that ended in Apr. 2026 was 0.00.
The historical rank and industry rank for Alzamend Neuro's 5-Year Yield-on-Cost % or its related term are showing as below:
ALZN's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.695 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Alzamend Neuro 5-Year Yield-on-Cost % Related Terms
ALZN vs SILO, BGMS, ENVB: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Alzamend Neuro's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzamend Neuro 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alzamend Neuro's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Alzamend Neuro's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Alzamend Neuro is calculated as
Alzamend Neuro (ALZN) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 28, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Alzamend Neuro and its competitors. According to the industry distribution chart, Alzamend Neuro ranks #999999 out of 150 companies in the Biotechnology industry.
Is Alzamend Neuro's 5-Year Yield-on-Cost % too high?
Alzamend Neuro's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Alzamend Neuro ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alzamend Neuro has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Alzamend Neuro's 5-Year Yield-on-Cost % compare to SILO and BGMS?
According to the Biotechnology industry distribution chart, Alzamend Neuro ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places Alzamend Neuro in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.70, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Alzamend Neuro and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alzamend Neuro's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzamend Neuro stock overvalued right now?
Alzamend Neuro (ALZN) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Alzamend Neuro's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Alzamend Neuro (ALZN), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
21GF Score
Get the complete analysis for ALZN
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALZN has been successfully added to your 
